stella
Colorectal CancerMay 2023Summary reviewed August 2026

Two-Drug Combo Extended Life by 3 Months for Advanced Colon Cancer Patients

Patients with advanced colon cancer that had stopped responding to treatment lived a median of 10.8 months on a two-drug combo, compared to 7.5 months on one drug alone. The combo also delayed cancer growth and kept patients feeling stronger for longer.

What the trial was testing

The SUNLIGHT enrolled 492 patients with colorectal cancer. The study was sponsored by Taiho Oncology, Inc. and tracked outcomes across the full group of patients who matched the trial's eligibility profile.

It was a large trial designed to confirm whether the treatment works well enough for wider use. Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.

What the results showed

Patients on the two-drug combo lived 3.3 months longer than those on one drug alone.

The New England journal of medicine · 2023 · NCT04737187

These findings — that patients lived 3.3 months longer on the two-drug combo than on one drug alone — were published in the The New England journal of medicine and represent the headline result of the study.

Researchers tracked outcomes across 492 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.

What this means for patients

For patients with colorectal cancer, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.

What you can do now

This combo is now an FDA-approved option for advanced colon cancer that has stopped responding to other treatments. If you're in this situation, ask your oncologist whether this combo might work for you. The study showed it extended life and delayed disease progression, though side effects like low white blood cell counts and nausea were common.

Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.

Open colorectal cancer trials

RecruitingInterventional study

Loop Ileostomy Closure:Stapled or Hand-sewn Anastomoses? Suture or Mesh Closure of the Stoma Site?

There are severel problems associated with the closing of a temporary loop-ileostomy after surgery for rectal cancer. The purpose of this study is to answer two questions: 1. The choice of anastomotic method - does it influence the postoperative course? 2. The use of a prophylactic mesh when closing the stoma site - will there be less hernias?

Gothenburg, Sweden +10 more
RecruitingInterventional study

The Vanguard Study: Testing a New Way to Screen for Cancer

The Vanguard Study is a feasibility study to explore several aspects of evaluating multi-cancer detection (MCD) tests in a future definitive randomized controlled trial. An MCD test measures markers in the blood in order to screen for multiple cancers simultaneously. There is a need to understand how MCDs may work as cancer screening tools. The goal of cancer screening is to reduce the burden of cancer by identifying cancers before they show symptoms or signs, when treatment is likely to be most effective. In this study, adults aged 45-75 without cancer will be randomly assigned to one of 3 groups: 2 separate MCD test groups or a control group. These two MCD tests will not be compared to each other but will be compared to cancers detected in the control group. This study will provide early information on how well MCD tests perform as cancer screening tools. It will also help researchers understand how patients and their doctors make decisions about their care when the MCD test result comes back as normal (negative) or abnormal (positive).

Pleasanton, California, United States +24 more